Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer: A Tissue Microarray Study

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3069-3075

  Resnick, Murray B ^a,c   Routhier, Justin ^a   Konkin, Tamako ^a   Sabo, Edmond ^b   Pricolo, Victor E ^a  

^a BROWN UNIVERSITY   (United States)

^b CARMEL MEDICAL CENTER   (Israel)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; BIOLOGICAL MARKERS; COLONIC NEOPLASMS; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE FIXATION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2442480522     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0462     Document Type: Article

References (42)

1. Allegra C, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2003;21:241-50.
2. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026-38.
3. McLeod HL, Murray GI. Tumor markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191-203.
4. Leichman CG. Predictive and prognostic markers in gastrointestinal cancers. Curr Opin Oncol 2001;13:291-9.
5. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
6. Zwick E, Hackel PO, Prenzel N, Ullrich A. The EGF receptor is a central transducer of heterologous signaling systems. Trends Pharmacol Sci 1999;20:408-12.
7. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979;48:193-216.
8. Chen WS, Lazar CS, Poenie M, et al. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature (Lond) 1987;328:820-3.
9. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):9-15.
10. Trusolino L, Comoglio PM. Scatter factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300.
11. Ghoussoub RA, Dillon DA, D'Aquila T, et al. Expression of c-MET is a strong independent prognostic factor in breast carcinoma. Cancer (Phila) 1998;82:1513-20.
12. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Aberrant expression of c-MET mRNA in human gastric carcinomas. Int J Cancer 1993;55:72-5.
13. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-MET proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862-6.
14. Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-MET expression in endometrial carcinoma. Cancer (Phila) 1998;82:520-30.
15. Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002;62:589-96.
16. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-8.
17. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with β-catenin. Science (Wash DC) 1993;262:1731-4.
18. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science (Wash DC) 1993;262:1734-7.
19. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995;92:3046-50.
20. Wong NA, Pignatelli M. β-catenin: a linchpin in colorectal carcinogenesis. Am J Pathol 2002;160:389-401.
21. Gunther K, Brabletz T, Kraus C, et al. Predictive value of nuclear β-catenin expression for the occurrence of distant metastases in rectal cancer. Dis Colon Rectum 1998;41:1256-61.
22. Hugh TJ, Dillon SA, Taylor BA, et al. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999;80:1046-51.
23. Maruyama K, Ochiai A, Akimoto S, et al. Cytoplasmic β-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology (Basel) 2000;59:302-9.
24. Chung GG, Provost E, Kielhom EP, et al. Tissue microarray analysis of β-catenin in colorectal cancer shows nuclear phospho-β-catenin is associated with a better prognosis. Clin Cancer Res 2001;7:4013-20.
25. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with β-catenin and p27kip1. Cancer (Phila.) 2002;95:2479-86.
26. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst (Bethesda) 1996;88:1442-55.
27. Greene FL, Page DL, Fleming ID, et al., editors. AJCC: cancer staging handbook: From the AJCC cancer staging manual. Edition 6. New York: Springer Verlag; 2002. p. 127-9.
28. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003;443:115-21.
29. Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990;77:1352-4.
30. Kluftinger AM, Robinson BW, Ouenville NF, Finley RJ, Davis NL. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992;1:97-105.
31. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (Phila) 1993;71:2454-60.
32. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human carcinoma cells. Clin Cancer Res 1995;1:19-31.
33. De-Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53 and Ki67 in colorectal liver metastasis and corresponding primary tumors. Hepatology 1998;284:971-9.
34. Saeki T, Salomon DS, Johnson GR, et al. Association of epidermal growth factor related peptides and type I receptor kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995;25:240-9.
35. Komuta K, Koji T, Izumi S, et al. Expression of epidermal growth factor receptor for messenger RNA in human colorectal carcinomas assessed by non-radioactive in-situ hybridization. Eur J Surg Oncol 1995;21:269-75.
36. Lee JC, Wang ST, Chow NW, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065-71.
37. Barozzi C, Ravaioli M, D'Errico A, et al. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer (Phila) 2002;94:647-57.
38. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur J Cancer 2002;38:2258-64.
39. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer (Phila) 2001;92:1331-46.
40. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
41. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003;39:1348-54.
42. Soong R, Powell B, Elsaleh H, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence on tumor site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-60.